{"entity":{"id":"inbrx-106","kind":"drug","name":"INBRX-106","aka":["Hexavalent OX40 agonist antibody"],"tldr":"INBRX-106 is an experimental monoclonal antibody from Inhibrx Biosciences in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.","summary":"INBRX-106 is a monoclonal antibody developed by Inhibrx Biosciences. The sponsor describes its target as OX40, which OnCo does not yet have a target page for. The sponsor states: A hexavalent OX40 agonist antibody designed to promote hyperclustering of OX40, giving more potent activation of the OX40 costimulatory pathway than traditional Fc-crosslinking-dependent bivalent OX40 antibodies. ClinicalTrials.gov describes the intervention as: INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06295731 (INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC), in head and neck squamous cell carcinoma. The largest, NCT06295731, plans to enrol 410 participants with primary completion expected 2029-05. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of INBRX-106","url":"https://clinicaltrials.gov/search?intr=INBRX-106"},{"label":"Sponsor pipeline page","url":"https://inhibrx.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["inhibrx"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06295731"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"A hexavalent OX40 agonist antibody designed to promote hyperclustering of OX40, giving more potent activation of the OX40 costimulatory pathway than traditional Fc-crosslinking-dependent bivalent OX40 antibodies.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/inbrx-106/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"company":[{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","route":"/companies/inhibrx/"}],"trial":[{"id":"nct06295731","kind":"trial","name":"INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","route":"/trials/nct06295731/"},{"id":"nct06353997","kind":"trial","name":"Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients","route":"/trials/nct06353997/"}],"target":[{"id":"tnfrsf4","kind":"target","name":"OX40 (TNFRSF4)","route":"/targets/tnfrsf4/"}]}}